Renal impairment associated with tenofovir disoproxil fumarate for antiretroviral therapy and HIV pre-exposure prophylaxis: An observational cohort study

2Citations
Citations of this article
17Readers
Mendeley users who have this article in their library.

Abstract

Background Tenofovir disoproxil fumarate (TDF) is associated with adverse renal outcomes when prescribed for HIV infection. There are few data concerning real-world renal outcomes amongst patients prescribed TDF for pre-exposure prophylaxis (PrEP). Methods and findings Data were extracted from 52 sexual health clinics across Australia from 2009–2019. All patients prescribed TDF-containing antiretroviral therapy and PrEP were included. Rates of renal impairment (a fall in eGFR to <60 ml/min/1·73m2) were calculated for people living with HIV (PLWHIV) prescribed TDF and HIV negative PrEP-users. Risk factors were assessed using Cox-proportional hazards models. Sensitivity analysis of risk using 1:1 propensity-score matching to adjust for potential imbalance in HIV and PrEP cohorts was conducted. 5,973 patients on PrEP and 1,973 PLWHIV were included. There were 39 (0.7%) instances of renal impairment in the PrEP group and 81 (4.1%) in the PLWHIV cohort (hazard ratio [HR]:0.35 95% confidence interval [CI]: 0.22–0.56). Rates of renal impairment were 4.01/1000 person-years (95%CI:2.93–5.48) in the PrEP cohort and 16.18/1000 person-years (95%CI:13.01–20.11) in the PLWHIV cohort (p<0.001). Predictors of renal impairment were: older age (40–49 years (HR:5.09 95%CI: 2.12–12.17) and 50–82 years (HR:13.69 95%CI: 5.92–31.67) (compared with 30–39 years) and baseline eGFR<90ml/min (HR:61.19 95%CI: 19.27–194.30). After adjusting for age and baseline eGFR the rate of renal impairment remained lower in the PrEP cohort (aHR:0.62 95%CI: 0.40–0.94, p = 0.023). In propensity-matched analysis using 1,622 patients per cohort the risk of renal impairment remained higher in the PLWHIV cohort (log-rank p = 0.001). Conclusion Patients prescribed TDF-based PrEP had lower rates of renal impairment than patients prescribed TDF for HIV infection. In propensity analysis, after matching for some risk factors, rates of renal impairment remained higher amongst patients with HIV.

References Powered by Scopus

Constructing a control group using multivariate matched sampling methods that incorporate the propensity score

4413Citations
N/AReaders
Get full text

Preexposure chemoprophylaxis for HIV prevention in men who have sex with men

4198Citations
N/AReaders
Get full text

Antiretroviral prophylaxis for HIV prevention in heterosexual men and women

2643Citations
N/AReaders
Get full text

Cited by Powered by Scopus

Cardiac and Renal Comorbidities in Aging People Living with HIV

4Citations
N/AReaders
Get full text

Association between tenofovir plasma trough concentrations in the early stage of administration and discontinuation of up to five years tenofovir disoproxil fumarate due to renal function-related adverse events in Japanese HIV-1 infected patients

0Citations
N/AReaders
Get full text

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Cite

CITATION STYLE

APA

Heron, J. E., McManus, H., Vickers, T., Ryan, K., Wright, E., Carter, A., … West, M. (2023). Renal impairment associated with tenofovir disoproxil fumarate for antiretroviral therapy and HIV pre-exposure prophylaxis: An observational cohort study. PLoS ONE, 18(2 February). https://doi.org/10.1371/journal.pone.0280339

Readers' Seniority

Tooltip

PhD / Post grad / Masters / Doc 2

50%

Professor / Associate Prof. 1

25%

Researcher 1

25%

Readers' Discipline

Tooltip

Medicine and Dentistry 2

33%

Nursing and Health Professions 2

33%

Biochemistry, Genetics and Molecular Bi... 1

17%

Immunology and Microbiology 1

17%

Article Metrics

Tooltip
Social Media
Shares, Likes & Comments: 19

Save time finding and organizing research with Mendeley

Sign up for free